Search results for "NAFLD"
Experts go ‘Beyond the Guidelines' to debate screening, management of NAFLD
Hepatologists from Beth Israel Deaconess Medical Center and University of Michigan Medical Center offered differing opinions on screening and management for nonalcoholic fatty liver disease (NAFLD).
https://gastroenterology.acponline.org/archives/2019/08/23/8.htm
23 Aug 2019
Risk and severity of NAFLD differ in men and women
Women have a significantly lower risk of developing nonalcoholic fatty liver disease (NAFLD) but a higher risk of developing advanced fibrosis from NAFLD, according to a systematic review and meta-analysis.
https://gastroenterology.acponline.org/archives/2020/05/22/3.htm
22 May 2020
Weight loss interventions may improve biomarkers of liver disease in NAFLD
In a meta-analysis of 22 studies in patients with nonalcoholic fatty liver disease (NAFLD), weight loss interventions were associated with improvements in alanine aminotransferase level, liver steatosis, histologic NAFLD activity score, and nonalcoholic steatohepatitis.
https://gastroenterology.acponline.org/archives/2019/07/26/3.htm
26 Jul 2019
NAFLD progression associated with increased mortality risk
Patients with stage F4 nonalcoholic fatty liver disease (NAFLD) have significantly increased risk for liver-related complications, type 2 diabetes, and all-cause mortality compared to those with earlier stages, an observational prospective study found.
https://gastroenterology.acponline.org/archives/2021/10/22/3.htm
22 Oct 2021
Score predicts hepatic decompensation among patients with NAFLD
Age, presence of diabetes, and platelet count were significant predictors of hepatic events up to 12 years from the time of nonalcoholic fatty liver disease (NAFLD) diagnosis, a retrospective study found.
https://gastroenterology.acponline.org/archives/2020/03/27/1.htm
27 Mar 2020
NAFLD practice guidance issued for screening, treatment
The guidance, from the American Association for the Study of Liver Diseases, notes that routine screening for nonalcoholic fatty liver disease (NAFLD) in a primary care setting or obesity clinics is not typically recommended due to uncertainties in long-term benefits and cost-effectiveness.
https://gastroenterology.acponline.org/archives/2017/07/28/2.htm
28 Jul 2017
Risk of liver-related death linked to increased fibrosis stage in NAFLD
The systematic review and meta-analysis included five studies of 1,495 adult patients with nonalcoholic fatty liver disease (NAFLD), encompassing 17,452 patient-years of follow-up.
https://gastroenterology.acponline.org/archives/2017/04/28/2.htm
28 Apr 2017
NASH management conflicts with guidelines in real-world setting, study finds
Researchers sought to learn how patient characteristics vary by stages of liver scarring and how U.S. physicians manage nonalcoholic steatohepatitis (NASH).
https://gastroenterology.acponline.org/archives/2023/05/26/2.htm
26 May 2023
Spotlight on statins and chronic liver disease
Recent studies found associations between statin use and decreased risks of severe liver disease and mortality in patients with chronic liver disease.
https://gastroenterology.acponline.org/archives/2023/05/26/5.htm
26 May 2023
Noninvasive score for fibrotic NASH designed for, validated in primary care settings
Levels of aspartate aminotransferase, high-density lipoprotein cholesterol, and HbA1c can be used to predict which patients might need referral to a subspecialist for fibrotic nonalcoholic steatohepatitis (NASH).
https://gastroenterology.acponline.org/archives/2022/04/22/1.htm
22 Apr 2022